Orthopedia Stock Price, News & Analysis

OrthoPediatrics (NASDAQ: KIDS), a company specializing in pediatric orthopedics, has scheduled its second quarter 2025 financial results release for August 5, 2025 after market close. The company will host a conference call the same day at 4:30 p.m. ET to discuss the results.

Investors can access both the live event and archived webcast through the company's website at www.orthopediatrics.com in the Events & Presentations section of the Investors page. The webcast recording will remain available for at least 90 days following the event.

OrthoPediatrics (NASDAQ: KIDS) has announced a major milestone in its Global POISE (Pediatric Orthopedic Implant Safety and Efficacy) Study, with over 600 implants now being monitored across more than 300 pediatric patients.

The multi-center, post-market, prospective clinical follow-up study, launched in 2023, now includes 13 active sites across Canada, the United States, Australia, New Zealand, and South Africa. The study encompasses 17 different implant types and aims to assess the safety and efficacy of OrthoPediatrics' implant devices, focusing on implant survival and identifying device-related adverse events.

OrthoPediatrics (NASDAQ: KIDS) announced its continued role as the exclusive Emerald Sponsor for the 2025 Pediatric Orthopaedic Society of North America (POSNA) annual meeting. The company will showcase its expanding pediatric-specific solutions, including OrthoPediatrics Specialty Bracing and Enabling Technologies, across three exhibit booths. As part of its long-term commitment to POSNA, OrthoPediatrics provides support through specialty symposiums, educational grants, and scholarships for attendees.

OrthoPediatrics (NASDAQ: KIDS) reported strong Q1 2025 financial results with total revenue of $52.4 million, up 17% year-over-year. The company helped a record 39,000 children during the quarter. Domestic revenue increased 19% to $40.9 million, while international revenue grew 11% to $11.5 million. Key growth drivers included Trauma & Deformity revenue (+14%) and Scoliosis revenue (+34%). Despite showing gross profit of $38.3 million (+19% YoY), the company reported a net loss of $10.7 million. OrthoPediatrics launched its 80th system, the VerteGlide™ System for Early Onset Scoliosis treatment. The company increased its full-year 2025 revenue guidance to $236.0-242.0 million, representing 15-18% growth, and expects its first positive free cash flow quarter in Q4 2025.

OrthoPediatrics (NASDAQ: KIDS) has announced the expansion of its Trauma and Deformity portfolio with the 3P™ Pediatric Plating Platform™ Hip System, marking the company's 5th FDA approval in 2025. This innovative plate and screw platform aims to modernize trauma and deformity correction treatment in lower extremities.

The beta launch of 3P Hip will be followed by 3P Small/Mini in early 2026, with additional systems planned for future release. This initiative represents one of the company's largest product developments in its Trauma and Deformity division, aimed at creating the most comprehensive modern plating portfolio in pediatric orthopedic history.

OrthoPediatrics (Nasdaq: KIDS), a company specializing in pediatric orthopedics, has announced it will release its first quarter 2025 financial results on May 7, 2025, after market close. The company will host a conference call the same day at 4:30 p.m. ET to discuss the results.

Investors can access both the live and archived webcast of the earnings call through the Events & Presentations section of the company's website at www.orthopediatrics.com. The webcast recording will remain available for at least 90 days following the event.

OrthoPediatrics (Nasdaq: KIDS) has announced the U.S. launch of the VerteGlide Spinal Growth Guidance System, marking their 80th system for treating pediatric musculoskeletal conditions. The system, recently FDA-cleared, is designed to treat Early Onset Scoliosis (EOS) in children under 10 years old who often experience pulmonary and digestive dysfunction.

The VerteGlide system aims to correct deformity while minimizing repeat surgeries until skeletal maturity. Initial surgeries are expected to begin at select children's centers during summer 2025. The technology was developed in partnership with pediatric orthopedic surgeons Dr. Richard McCarthy and Dr. Scott Luhmann, utilizing Shilla™ technology licensed from Medtronic.

OrthoPediatrics (Nasdaq: KIDS), a company specializing in pediatric orthopedics, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference.

The company's leadership team, including President & CEO Dave Bailey and COO/CFO Fred Hite, will engage in a fireside chat during the conference.

Investors and interested parties can access the audio webcast of the discussion through OrthoPediatrics' investor relations website at http://ir.orthopediatrics.com, with a replay option available after the event.

OrthoPediatrics (Nasdaq: KIDS) has been named one of the 2025 Best Places to Work in Indiana for the 9th time by the Indiana Chamber of Commerce. The pediatric orthopedics-focused company joins 150 other organizations from over 20 industries across the state in this 20th edition of the recognition program.

Company President & CEO David Bailey emphasized their commitment to fostering an engaging and inclusive culture, highlighting continuous investments in employee development and meaningful career experiences. The recognition reflects the company's success in building a positive workplace environment focused on helping children.

Indiana Chamber President Vanessa Green Sinders noted the program's importance in evaluating workplace culture amid intense talent competition. The final rankings will be revealed at an awards ceremony on April 30th, 2025, followed by publication in the Chamber's BizVoice® magazine.